Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00111696 |
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
Condition | Intervention | Phase |
---|---|---|
Malignant Melanoma |
Biological: MEDI-522 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Bio-availability Study |
Official Title: | Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Advanced Malignant Melanoma |
Enrollment: | 18 |
Study Start Date: | May 2005 |
Study Completion Date: | November 2007 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
MEDI-522
|
Biological: MEDI-522
Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
University Of Pittsburgh Cancer Institute | |
Pittsburgh, Pennsylvania, United States, 15213 |
Principal Investigator: | Stergios Moschos, MD | University of Pittsburgh |
Responsible Party: | MedImmune LLC ( Lawrence Danel-Moore, M.D., PhD, VP, Clin. Dev. ) |
Study ID Numbers: | MI-CP121, CRRI #0305014, UPCI 05-025 |
Study First Received: | May 24, 2005 |
Last Updated: | November 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00111696 |
Health Authority: | United States: Food and Drug Administration |
Antibodies, Monoclonal Neuroectodermal Tumors Antibodies Nevus, Pigmented Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Nevus Immunoglobulins Neuroendocrine Tumors Melanoma |
Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas |